Aegle Therapeutics is a first-in-class, phase 1/2a biotechnology company isolating extracellular vesicles including exosomes ("EVs") secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa ("DEB"), a rare genetic pediatric connective tissue disorder. Aegle's EV therapy, using its proprietary platform isolation technology, is cell-free and has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. Aegle's EVs deliver COL7, COL7A1 mRNA and then regenerative signals of MSCs to diseased cells and present a unique, multifaceted approach to DEB. Aegle believes its EV therapy has the potential for functional regeneration and organization of complex tissue structures that can accelerate and enhance healing, reduce scarring, minimize contraction and improve overall cosmesis.